Janus Henderson Group PLC Purchases 101,358 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Janus Henderson Group PLC grew its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,581,642 shares of the company's stock after purchasing an additional 101,358 shares during the quarter. Janus Henderson Group PLC owned about 9.54% of Mirum Pharmaceuticals worth $189,481,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jones Financial Companies Lllp grew its position in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $69,000. AlphaQuest LLC grew its position in shares of Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter. Summit Investment Advisors Inc. grew its position in Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after buying an additional 312 shares in the last quarter. Finally, Avanza Fonder AB acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $189,000.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, Director Patrick J. Heron bought 1,335 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was bought at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the completion of the purchase, the director now owns 163,643 shares of the company's stock, valued at approximately $7,457,211.51. The trade was a 0.82% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jolanda Howe sold 57,606 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the transaction, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. This trade represents a 92.25% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,764 shares of company stock valued at $4,109,161. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM traded down $0.27 during trading on Friday, reaching $45.01. 219,847 shares of the company traded hands, compared to its average volume of 524,834. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock's 50 day moving average price is $42.96 and its two-hundred day moving average price is $44.47. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -22.28 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.83 and a 1-year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The company had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.54) earnings per share. As a group, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. JMP Securities lifted their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. Finally, Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $60.64.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.